A Study to Evaluate the Safety and Efficacy of NT-88

NCT07509801 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-04-03

No results posted yet for this study

Summary

A study to evaluate the safety and preliminary efficacy of Zuozhu Daxi in patients with chronic heart failure with mildly reduced ejection fraction

Conditions

  • Heart Failure With Mildly Reduced Ejection Fraction

Interventions

DRUG

Conventional therapeutic drugs

Conventional therapeutic drugs

DRUG

NT-88

Conventional therapeutic drugs+NT-88

Sponsors & Collaborators

  • Guangzhou Manjing biomedicine technology co., ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-30
Primary Completion
2027-02-25
Completion
2027-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07509801 on ClinicalTrials.gov